Skip to content
  • info@BioLifeSolutions.com
  • 1.866.424.6543
  • Toggle search form
  • Toggle shopping cart 0

    Cart

  • Products
    • CryoStor®
      • CryoStor CS10
      • CryoStor CS5
      • CryoStor CS2
      • CryoStor CSB
    • HypoThermosol®
      • HypoThermosol®
      • HypoThermosol for Hair
    • ThawSTAR® Products
      • ThawSTAR CB
      • ThawSTAR CFT2
      • AT6
      • CFT1.5
      • CFT2 Confirmation Vials
      • Warranty and PM
      • IOP Qualification Packet
      • BioT ULT Transporter
      • BioT LN2 Transporter
      • BioT ULT Mobile Workstation
    • BloodStor®
      • BloodStor 100
      • BloodStor 55-5
      • BloodStor 27
    • Cell Thawing Media®
      • 10% Dextran 40 (IN 0.9% NaCl)
      • 10% Dextran 40 (IN 5% Dextrose)
    • All Products
  • Resources
    • Certificate of Analysis
    • Blog
    • Events
    • BioPreservation Today
    • White Papers
    • Press Releases
  • Evidence
    • Resource Links
  • Company
    • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Quality Management System
    • Distributors
    • Current Job Openings
  • Investors
    • Investors Home
    • Governance
    • Press Releases
    • Financials
    • Stock Information
    • Management Team
    • Investor Contact
  • Contact
    • General Inquiries
    • ThawSTAR Inquiries
    • Master File Request
    • SDS Request Form
    • Sample Request
    • evo Support Request
  • Ask the Scientists
  • ORDER
Close navigation
  • Primary Menu
logo

BioLife Solutions

Biopreservation Tools For Cells, Tissues, and Organs

Close search

Search

Search for:
Home/Blog/Tag: “T-cell receptor”

Tag: T-cell receptor

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S. and Aplin, A. E.  Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis. Cancer Discovery. 2019; 10(2), 254-269.  doi: 10.1158/2159-8290.cd-19-0672

Read More

How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?

Chen, L. N., Collins‐Johnson, N., Sapp, N., Pickett, A., West, K., Stroncek, D. F., Panch, S. R.  How do I structure logistic processes in preparation for outsourcing of cellular therapy manufacturing?  Transfusion. August 2019; 59 (8), 2506-2518.  doi:10.1111/trf.15349

Read More

Off the shelf T cell therapies for hematologic malignancies

McCreedy, B. J., Senyukov, V. V., Nguyen, K. T.   Off the shelf T cell therapies for hematologic malignancies.  Best Practice & Research Clinical Haematology 2018; 31(2), 166-175.  doi: 10.1016/j.beha.2018.03.001.

Read More

High fidelity hypothermic preservation of primary tissues in organ transplant preservative for single cell transcriptome analysis

Wang, Penland, Gokce, Croote, Quake. High fidelity hypothermic preservation of primary tissues in organ transplant preservative for single cell transcriptome analysis. BMC Genomics (2018) 19:140. https://doi.org/10.1186/s12864-018-4512-5

Read More

Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults

Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Spratt K, Hoglund V, Lindgren C, Oron A, Li D, Riddell S, Park J, Jensen M. Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults. Blood 2017 :blood-2017-02-769208. doi:…

Read More
Search for:

Blog Archives

Signup Area

    Sign Up for Email Updates

    Biolife Logo

    • Products
    • Company
    • Evidence
    • Investors
    • Blog
    • Ask the Scientists
    • Press Releases
    • Contact
    © 2019 BioLifeSolutions Inc.  All Rights Reserved    |    Terms & Conditions    |    Privacy
    • twitter
    • linkedin
    • facebook